Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 9/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 9/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 9/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 9/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 9/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 9/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8334678 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4877544 | 1.00 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9597689 | 0.92 | GRIN2D (0.84) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9599421 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9598408 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9598395 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9598049 | 0.91 | GRIN2D (0.83) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8906265 | 0.90 | GRIN2D (0.82) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9597701 | 0.90 | GRIN2D (0.82) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL9209443 | 0.89 | GRIN2D (0.80) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2008088820-A2 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196354-A1 | GLUTAMATE RECEPTOR ANTAGONISTS AND METHODS OF USE | GRM5, GRM1, GRM3 | GRIN2D 30/4885GRIN3B 17/4885GRIN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.